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Microsatellite instability has been proposed as an alternative pathway of colorectal carcinogenesis. The aim of this study was to
evaluate the interest of immunohistochemistry as a new tool for highlighting mismatch repair deﬁciency and to compare the
results with a PCR-based microsatellite assay. A total of 100 sporadic proximal colon adenocarcinomas were analysed. The
expression of hMLH1, hMSH2 and hMSH6 proteins evaluated by immunohistochemistry was altered in 39% of the cancers,
whereas microsatellite instability assessed by PCR was detected in 43%. There was discordance between the two methods in
eight cases. After further analyses performed on other tumoural areas for these eight cases, total concordance between the
two techniques was observed (Kappa=100%). Our results demonstrate that immunohistochemistry may be as efﬁcient as
microsatellite ampliﬁcation in the detection of unstable phenotype provided that at least two samples of each carcinoma are
screened, because of intratumoural heterogeneity.
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Currently, there is accumulating evidence that some colorectal
carcinomas have a different proﬁle from others. Two apparently
independent mechanisms of instability are recognised in colorectal
cancer: chromosomal instability and microsatellite instability. The
ﬁrst group is characterised by allelic losses (LOH for loss of hetero-
zygosity), chromosomal ampliﬁcations, and translocations in
colorectal cancer cells. The second group is deﬁned by an unstable
phenotype (microsatellite instability (MSI) or replicative error
(RER) positive) determined by genetic or epigenetic alterations of
MisMatch Repair (MMR) genes. This phenotype is one of the
major characteristics of tumours developing in genetically predis-
posed Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
patients (Aaltonen et al, 1993; Aaltonen, 1998). It is also involved
in the occurrence of approximately 10 to 15% of sporadic colorec-
tal carcinomas.
Colorectal carcinomas with MSI phenotype display particular
clinical, pathological and prognostic features and their susceptibil-
ity to chemotherapy seems to be different (Branch et al, 1995;
Boland, 1996; Claij and Riele, 1999; Elsaleh et al, 2000). Thus
the determination of the molecular status of the tumour is a poten-
tially important factor in the clinical and therapeutic management
of these patients. A reliable PCR-based microsatellite instability test
can be used to identify tumours with defective MMR, but this is
time consuming and requires the services of a molecular genetics
laboratory. Immunohistochemistry can now be performed (Thibo-
deau et al, 1996), and this technique could be a useful alternative
strategy to molecular biology.
The aim of this study was to evaluate the interest of immuno-
histochemistry (IHC) as a new tool for detecting mismatch
repair deﬁciency and to compare the results with a PCR-based
microsatellite assay.
PATIENTS AND METHODS
Patients and samples
One hundred and eight proximal colon carcinomas, resected in
Dijon University Hospital between September 1996 and November
2000, were included in this study. They were deﬁned as proximal
to the splenic ﬂexure (Ponz de Leon et al, 1992). Eight cases were
excluded (three men and ﬁve women) since DNA ampliﬁcation
was not possible. Thus a total of 100 proximal adenocarcinomas
were analysed. There were 41 males and 59 females. No patient
had HNPCC syndrome.
Immunohistochemistry (IHC)
The MMR protein status was determined by an immunohisto-
chemistry assay using a super sensitive immunodetection system
(Biogenex, San Ramon, CA, USA) and Amino Ethyl Carbazol as
chromogen. Five mm-thick sections of 10% formalin-ﬁxed, parafﬁn
embedded cancer slides were ﬁrst placed in 10 mM citrate buffer
(pH 6) and autoclaved for 5 min for antigen retrieval. The tissue
sections were then incubated for 1 h with the primary monoclonal
antibodies hMLH1 (1/100, Pharmingen, San Diego, CA, USA),
hMSH2 (1/100, Pharmingen) and hMSH6 (1/800, Transduction
Laboratories, San Diego, CA, USA). All the results were scored
without knowledge of microsatellite instability status. Carcinomas
were considered to demonstrate inactivation of the MMR system
when there was complete absence of a detectable nuclear signal
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Intact nuclear staining of adjacent non neoplastic epithelium or of
inﬁltrating lymphocytes was used as internal positive control and
was required for adequate evaluation.
Microsatellite ampliﬁcation
For 56 cases, the DNA was extracted from freshly frozen tissue
samples from a different area from the one employed for the
IHC assay. For 44 cases, DNA was extracted from the parafﬁn
embedded tissues used for the IHC. The DNA was extracted after
macrodissection in order to reduce contamination by non-neoplas-
tic inﬂammatory and stromal cells. The adjacent normal mucosa
was sampled separately and used as a control. Two mononucleo-
tide microsatellite markers (BAT26 and BAT25) were ﬁrst used
to evaluate the genomic instability of each tumour. When the
two markers gave conﬂicting results three other dinucleotide
microsatellites D2S123, D5S346, D17S250 were then ampliﬁed.
According to the deﬁnition of Boland et al (1998), if at least two
of these ﬁve loci were modiﬁed the cancer was considered as
unstable. PCR was carried out in a 50 ml reaction volume contain-
ing 100 ng of genomic DNA, 8 pmole of each primer with one
primer of each pair ﬂuorescently labelled for allele detection (Life
Technologies SARL, France). The PCR was performed on an
Omn-E Hybaid thermocycler. Each PCR product was mixed with
0.5 ml Genscan 500 TAMRA size standard (Applied Biosystems,
France) and 18.5 ml formamide and denatured for 5 min at
958C. The PCR fragments were separated using an ABI Prism
310 instrument (Applied Biosystems) and further analysed by using
GeneScan and Genotyper software (Applied Biosystems). Instability
was evaluated by the presence of new PCR products after cancer
DNA ampliﬁcation that were absent in PCR products of the corre-
sponding normal DNA ampliﬁcation. Microsatellite status was
assessed without knowledge of the IHC results.
Additional analysis
When the results of the two techniques were divergent, immuno-
histochemistry and microsatellite ampliﬁcation were performed
again. The IHC analysis was carried out on two to ﬁve other blocks
per carcinoma and microsatellites were ampliﬁed from the DNA
extracted after macrodissection, taking into account the immunos-
taining pattern.
Histopathological analysis
The haematoxylin-eosin stained slides were reviewed by two
pathologists who were not aware of the MSI status. All the cancers
were adenocarcinomas. Differentiation grading was based on the
formation of glands: in well-differentiated cancers, more than
90% of the tumour cells formed glands; moderately-differentiated
30 to 90%; poorly-differentiated less than 30%. Mucin secretion
was categorised as absent (no mucin production), focal intracyto-
plasmic (550%), focal extracellular (550%), while mucinous
cancers corresponded to carcinomas with areas of extracellular
mucin greater than 50%. Lymphocytic stromal reaction was classi-
ﬁed in sheets, aggregates or Crohn’s like lymphoid reaction which
was deﬁned as pronounced lymphoid reaction to the tumour
composed of lymphoid follicles with germinal centres at the
tumour edge (Kim et al, 1994; Jass et al, 1998). The TNM system
of UICC was used for tumour staging (Hermanek et al, 1997).
Statistical analysis
The associations between the clinicopathological features of the
cancers and the MSI status were evaluated with the Pearson Chi-
square test of heterogeneity. The concordance between the two
IHC and PCR-based assay outcomes was analysed with the
Kappa-statistic measure. Analysis was carried out using the STATA
software package (Stata software 1984–99. Stata Corporation, 702
University Drive, East College Station, Texas, TX 77840, USA).
RESULTS
Clinical and pathological characteristics
The mean size of tumours was 33.1+2.6 cm
2. Of the 100 speci-
mens of right-sided colon cancers, 10 were poorly differentiated.
Mucin secretion was observed in 42% of the cases. It was focal
intracytoplasmic in 27 cases and focal extracellular in 11 cases.
Four mucinous carcinomas were diagnosed. Peritumoral lympho-
cytic inﬁltration was seen as nodules or follicles in 70% of the
cases. According to the TNM system of staging, eight carcinomas
were stage I, 60 stage II, 24 stage III and eight stage IV.
Immunohistochemistry (IHC) results (Table 1)
IHC analysis showed no nuclear staining of carcinoma cells for at
least one of the three MMR proteins in 39 of the 100 cases. Of
these, 74.4% (29 cases) presented a loss of the signal of only one
protein, 20.5% (eight cases) presented a loss of the expression of
two proteins and 5.1% (two cases) a loss of the expression of all
three proteins.
The link between the clinicopathological features of the 100
right-sided colon adenocarcinomas and the MSI status evaluated
by IHC was assessed (Table 2). The mean size of the cancers
tended to be greater in the MSI cancers: 39 cm
2+4 against
30 cm
2+3.3 among the 61 stable cancers (NS). The MSI carcino-
mas were more likely to be poorly differentiated than the stable
(MSS) cancers: 23.1% of the cancers showing loss of MMR-protein
expression were poorly differentiated whereas only 1.6% of the
cancers with normal nuclear expression of MMR proteins were
poorly differentiated (P=0.001). A mucinous component was more
frequently observed in the MSI cancers: 69.2% of the MSI cancers
were characterised by mucin production whereas 24.6% of the
stable cancers presented mucin secretion (P50.001). Moreover,
84.6% of the MSI cancers had a lymphoid stromal reaction (folli-
cles or nodules) while this same stromal reaction was observed in
60.7% of the MSS cancers (P=0.01).
Microsatellite instability analysis
The PCR-based assay performed independently from the IHC
analysis on the 100 carcinomas revealed microsatellite instability
phenotype (MSI) in 43 cancers. Both BAT26 and BAT25 loci were
involved in genomic instability in 38 cases. In the last ﬁve samples,
BAT25 and BAT26 loci ampliﬁcations gave contradictory results.
So three other microsatellites were investigated. In one case
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Table 1 Expression of the three MMR proteins analysed by IHC among
the 39 MSI carcinomas
MMR proteins expression Number of cases
MLH1 MSH2 MSH6 among the 39 MSI %
7 + + 23 59
+ 7 + 2 5.1
++7 4 10.3
77+ 2 5.1
7 + 7 5 12.8
+ 77 1 2.6
777 2 5.1
7: loss of the protein expression, +: expression of the protein
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had also shifted, which led us to consider this case as unstable
(MSI). For the other four cases, BAT26 was stable and BAT25
unstable, but at least one of the other loci was modiﬁed; these
cancers were also considered as unstable (MSI). As regards the
other 57 cancers, no instability was detected at any locus analysed.
Only a shift for the BAT26 locus in one tumour was noticed; the
other four loci were unchanged. Thus, the tumour phenotype was
regarded as stable (MSS).
Concordance between IHC and PCR to assess the MSI
status
When BAT25 and BAT26 ampliﬁcations were performed on DNA
extracted after macrodissection from an area of the cancer on
which IHC had been done, the results of the MSI status were
the same in 43 of the 44 cases: 19 were unstable after PCR
(MSI) and showed a loss of at least one MMR protein (MSI), 24
were stable (MSS) and presented normal immunostaining of the
three proteins (MSS). The divergent case presented normal expres-
sion of the three MMR proteins but microsatellite instability after
PCR. Thus the IHC method was nearly as efﬁcient as the molecular
method when the investigations were performed on the same tissue
sample (Kappa=95%).
When DNA was extracted from a frozen sample taken from a
different area from the one used for the IHC study, there was
agreement between the two methods for MSI status in 49 out of
56 cases: 18 were unstable after PCR (MSI) and showed a loss of
at least one MMR protein (MSI), 31 were stable (MSS) and
presented normal immunostaining for the three proteins (MSS).
There was disagreement between the two tests in seven cases: ﬁve
cases were characterised by normal expression of the three MMR
proteins but microsatellite instability after PCR. The last two cases
had lost the expression of hMLH1 or of both hMLH1 and hMSH2
but no microsatellite instability was detected by PCR. Thus, the
concordance between the two techniques can be considered as
moderate when the analysis is performed on two different tissue
samples (Kappa=73.7%).
Thus, at the end of the ﬁrst round of analyses, the results from
the two techniques in a total of eight cases were discordant.
Secondary analyses of the 8 ‘discordant cases’
For one case, for which DNA was extracted from the parafﬁn
embedded sample, a focal lack of hMLH1 staining was discovered
when IHC was performed on the same tissue sample and on other
additional samples. Nevertheless, this event was more frequent
when DNA was extracted from a frozen sample that was different
from the parafﬁn embedded sample used for IHC. In fact, for the
seven other discordant cases, in which the two techniques were
performed on two different areas of the tumour, we noticed
heterogeneous staining on the supplementary blocks. However,
the same patterns (ﬁve MMR efﬁcient and two MMR deﬁcient)
were found again when IHC was performed on the original tissue
sample. The different areas deﬁned by immunohistochemistry
(regions of expression or of extinction) were separated and DNA
was extracted. We again performed ampliﬁcations of BAT25 and
BAT26 loci on the DNA samples. The results of the PCR analysis
were given without knowledge of the immunohistochemistry data.
In all cases, microsatellite instability was detected with both
markers in the areas of loss of IHC staining. In the same way,
no microsatellite instability was noticed on the DNA samples
extracted from areas with normal expression of the three proteins.
Thus, the two methods of evaluation of the unstable status were
equally informative when they were performed on the same area.
Pathological features of the eight heterogeneous cancers
In the eight heterogeneous cases, the foci showing mismatch repair
deﬁciency were not usually limited to minor subclones. Heteroge-
neity concerned either a large area in a block or larger regions in
different blocks of the same cancer. The heterogeneity involved
one to three MMR proteins: in two cases the three proteins, in four
cases two proteins (hMLH1 and hMSH6) and in two cases one
protein (either hMLH1 or hMSH6). Sometimes the foci of MMR
deﬁciency were superimposed, elsewhere mutually exclusively
expressed.
The eight adenocarcinomas were located in the caecum (four), in
the ascending colon (three) and in the transverse colon (one). One
cancer was poorly differentiated whereas the seven remaining cases
were moderately or well-differentiated. Mucin was observed in four
cancers and a lymphoid reaction as nodules or follicles was seen in
seven cases. Seven patients were stage II and one stage IV.
DISCUSSION
In recent years, much progress has been made in the understanding
of the molecular genetics of colorectal carcinoma (Fearon and Vogel-
stein, 1990). It is now widely admitted that microsatellite instability
is an alternative genetic pathway in colorectal carcinogenesis. Testing
tumours for the presence of underlying MMR deﬁciency requires the
services of a molecular genetics laboratory and cannot be performed
routinely. The evaluation of MMR deﬁciency by the IHC technique
is based on the loss of nuclear detection of at least one of the MMR
proteins in the cancer cells. It has been suggested that immunohisto-
chemistry could represent an alternative strategy to molecular
biology (Thibodeau et al, 1996). This study indicates that IHC detec-
tion of the MMR proteins may be as efﬁcient as a PCR based assay
for screening MMR deﬁciency in certain conditions.
Analysing a total of 100 carcinomas, we have conﬁrmed the
association between MSI positivity and the loss of protein expres-
sion reported in other studies (Thibodeau et al, 1996; Dietmaier et
al, 1997; Cawkwell et al, 1999). After the ﬁrst analysis, immuno-
chemistry of hMLH1, hMSH2 and hMSH6 proteins identiﬁed 39
MSI carcinomas. This percentage (39%) is slightly higher than
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Table 2 Relationship between the clinicopathological features of adeno-
carcinomas and the RER status evaluated by IHC
All MSI MSS
samples (n=39) (n=61)
IHC analysis (n=100) n (%) n (%)
Patients
Gender n
Male 41 13 (33.3) 28 (45.9)
Female 59 26 (66.7) 33 (54.1)
Mean (+s.e.) size of the cancer (cm
2) 33.1+2.6 39+43 0 +3.3
Histologic features n (%)
Grade
Poorly differentiated 10 9 (23) 1 (1.6)**
Well or moderately differentiated 90 30 (76.9) 60 (98.4)
Mucin formation
Absent 58 12 (30.8) 46 (75.4)**
Present 42 27 (69.2) 15 (24.6)
Lymphoid reaction
Sheets 30 6 (15.4) 24 (39.3)*
Nodules or follicules 70 33 (84.6) 37 (6.7)
Pathological stage
I 8 2 (5.1) 6 (9.8)
II 60 25 (64.1) 35 (57.4)
III 24 11 (28.2) 13 (21.3)
IV 8 1 (2.6) 7 (11.5)
Signiﬁcance of the Chi
2 test for comparison between MSI status noted as follows:
*P50.01, **P50.001.
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which varied between 23.1 and 33% (Kim et al, 1994; Cawkwell
et al, 1999; Chao et al, 2000; Hemminki et al, 2000). These studies
were only performed with hMLH1 and hMSH2 whereas in the
present series, the use of the hMSH6 antibody enabled us to iden-
tify 10.3% of the MSI cases (i.e. 4% of the 100 cases). As recently
reported (Thibodeau et al, 1998), we also noted a preponderance of
hMLH1 abnormalities over hMSH2 defects (overall 5:1) and over
hMSH6 deﬁciency (overall 3:1). As the loss of hMLH1 expression
correlates with hypermethylation of its promoter (Kane et al, 1997;
Herman et al, 1998), we hypothesised that an excess of hMLH1
abnormalities could be produced since the hMSH2 promoter is less
likely to be inactivated via this mechanism (Cawkwell et al, 1999).
One patient had a lack of expression of hMLH1 and hMSH2,
suggesting somatic mutations of both of these genes during tumour
progression, or an inherited defect in one gene and a somatic
alteration of the other.
An interesting point of the study was the discovery of a discre-
pancy between the two methods according to the area of analyses.
When the DNA was extracted from the carcinomatous area on
which IHC had been performed, one (2.3%) IHC negative test
(i.e. MMR deﬁciency missed) was found out of the 44 cases of
the ﬁrst group. When IHC was performed again on this sample,
we noticed that nuclear immunostaining was not diffuse but focal
with a regional loss of hMLH1. In this case, the high sensitivity of
PCR assay was able to detect and to amplify instability even though
it concerned only a small number of cancerous cells. Furthermore,
the parafﬁn block had been exhausted for DNA extraction. Then,
we can hypothesise that this enabled us to discover intratumoural
heterogeneity of hMLH1 expression between the ﬁrst section and
the following ones. In the same way, ﬁve IHC negative tests
(8.9%) were observed when the DNA was extracted from carcino-
matous areas different from those on which IHC had been carried
out (56 cases) (second group). Two PCR negative tests (3.6%) also
showed a loss of the IHC signal. We ﬁrst interpreted this discre-
pancy as the result of the use of different techniques. In the
second round of analyses, this fact was explained by the presence
of intratumoural heterogeneity.
Regional variability of hMSH6 expression was noticed in ﬁve of
the eight heterogeneous cases. This could be interpreted as a
secondary event acquired after hMLH1 deﬁciency. This fact had
previously been noticed by Samowitz and Slattery (1999) concern-
ing the focal presence of a frameshift mutation in four coding
mononucleotide repeats (MSH6, IGFIIR, BAX and MSH3).
According to the authors, this was consistent with a somewhat later
time of acquisition of these mutations. Nevertheless, this explana-
tion is not valid for the cases where hMSH6 was the only focal
deﬁcient protein. This alteration could not be interpreted as a germ
line mutation (since the lack of expression was focal), but as an
independent event of the hMLH1 status, or as the consequence
of the alteration of another MMR protein not studied in this work.
The contemporary presence of areas with normal staining for
the three MMR proteins (and no instability of BAT25 and
BAT26) and regions with loss of MMR protein expression (and
microsatellite instability at the molecular level) is more difﬁcult
to explain in the light of our present knowledge on the biological
and genetic characteristics of these tumours. These results raise the
question of the existence of genuine mixed tumours. In order to
determine the existence of loss of heterozygosity, we genotyped
different areas of the tumours after macrodissection. For this
purpose, ﬁve microsatellite loci mapped to 18q were typed on
normal and tumour DNA. Unfortunately, we were unable to deter-
mine reliable genotyping in tumour DNA extracted from parafﬁn
embedded tissue sections. This negative result is probably due to
the low quality of the DNA extracted from formalin ﬁxed, parafﬁn
embedded samples (Coulet et al, 2000). So we were not able to
determine whether these tumours showed partly chromosomic
instability. MSI positive tumours have particular clinical and histo-
pathological features (Lothe et al, 1993; Thibodeau et al, 1993,
1998; Kim et al, 1994; Risio et al, 1996; Ru ¨schoff et al, 1997; Jass
et al, 1998; Gafa et al, 2000). In our series, the different features
associated with MSI status conformed with the characteristics
described in the literature: the presence of a mucinous component,
rather poor differentiation, a Crohn’s like lymphoid stromal reac-
tion and a trend towards a tumour of a larger size. These traits
were compared with those of the eight cancers exhibiting heteroge-
neous MMR deﬁciency, and no signiﬁcant characteristic allowed us
to distinguish these ‘heterogeneous’ cancers from other MMR deﬁ-
cient cases.
Additionally, the IHC MMR-protein analysis would be helpful
for the identiﬁcation of a high-risk group of individuals having
HNPCC syndrome. In contrast to microsatellite test, IHC identiﬁes
speciﬁcally either hMLH1, hMSH2, or hMSH6 as the underlying
inactivated gene. Therefore it directs germline mutation analysis
to one gene, and saves unnecessary analyses of other MMR genes
in HNPCC patients.
In conclusion, the evaluation of MSI status can be accurately
appreciated by both methods if at least two samples from different
areas of each cancer are analysed. This raises the problem of
sampling for giving an accurate evaluation of the unstable status
of the cancer. It would be interesting to screen several samples
of the 100 cancers analysed for MMR lack with the aim to evaluate
the level of intratumoural variability. It would enable us to estab-
lish the minimum number of samples required for the most
efﬁcient evaluation of MMR deﬁciency.
Nevertheless, immunohistochemical analyses of two tissue
samples with three antibodies would require at least six tissue
sections for each tumour. Accordingly, the workload and costs
for histopathology laboratories would be much greater. This is
an important issue taking into account the possibility to introduce
immunohistochemical analysis of MMR protein expression as a
routine diagnostic test and would provide valuable management
information in addition to the histopathological assessment of
tumour stage and grade. This is all the more important since the
predictive value of the MSI status in the good response to
chemotherapy has recently been stressed (Elsaleh et al, 2000;
Hemminki et al, 2000; Watanabe et al, 2001).
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